Company
AbbVie
North Chicago, Illinois pharmaceutical company spun off from Abbott Laboratories in 2013; acquired tavapadon through its $8.7 billion purchase of Cerevel Therapeutics in 2024, alongside Humira, Skyrizi and Rinvoq.
1 story
Regulatory News has published 1 story about AbbVie on 4 October 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 4 October 2026.
This page is generated from Regulatory News’ editorial coverage of AbbVie. It is not an advertisement.
Products in our coverage
Our coverage
